DNDi announces new Director of Neglected Tropical Diseases

Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme

DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.

Matichon Online: “คร.ร่วมหลายหน่วยงานชูความสำเร็จโครงการวิจัยยารักษาผู้ป่วยไวรัสตับอักเสบซี”

Matichon Online [7 May 2018] “คร.ร่วมหลายหน่วยงานชูความสำเร็จโครงการวิจัยยารักษาผู้ป่วยไวรัสตับอักเสบซี” – “Many organizations join in the success of the drug research program to treat patients with hepatitis C” Click here to read the article

MGR Online: “วิจัยพบยาคู่ใหม่ “โซฟอสบูเวียร์+เรวิดาสเวียร์” รักษา “ตับอักเสบซี” หายขาด 96-100%”

MGR Online [7 May 2018] “วิจัยพบยาคู่ใหม่ ‘โซฟอสบูเวียร์+เรวิดาสเวียร์’ รักษา ‘ตับอักเสบซี’ หายขาด 96-100%” – “New drug discovery ‘sofosbuvir + ravidasvir’ treatment ‘hepatitis C’ cured 96-100%” Click here to read the article

Forum Entwicklung

14 August 2018 
Frankfurt, Germany
Graeme Bilbe – discussion on medical care in developing countries

22nd International AIDS Conference

23-27 July 2018
Amsterdam, the Netherlands

Side event on ending paediatric HIV, presentation on the LIVING study on paediatric HIV, poster discussion on TB/HIV co-treatment, and poster on caregiver adherence to oral lopinavir/ritonavir pellets to treat children.

Also: pre-conference workshop session on viral suppression in children taking oral LPV/r

Gigazine [14 April 2018]

“高価な「C型肝炎治療薬」の効果を保ったまま安価で提供するための取り組みが進行中” – “Efforts to provide low cost while maintaining efficacy of ‘expensive hepatitis C treatment’ is ongoing”

Click here to read the article

Drug approved in Argentina for treatment of Chagas disease in children

Buenos Aires, Argentina – 13 April 2018
Argentina has approved the paediatric indication of a drug used for treatment of Chagas disease, benznidazole, which will now be available in 12.5 mg pills, the dose required to treat children under the age of 2. The indication was approved by the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT).